Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

s0122297

—

ef817492-901e-5f40-86d9-a282272bc712

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • ANGIOGENESIS+0.400
  • UV_RESPONSE_DN+0.400
  • ESTROGEN_RESPONSE_EARLY+0.300
  • HEDGEHOG_SIGNALING+0.300
  • KRAS_SIGNALING_DN+0.300
  • MYOGENESIS+0.300
  • NOTCH_SIGNALING+0.300
  • TGF_BETA_SIGNALING+0.300
  • WNT_BETA_CATENIN_SIGNALING+0.300

Top 10 suppressed

  • E2F_TARGETS-0.600
  • INTERFERON_ALPHA_RESPONSE-0.600
  • OXIDATIVE_PHOSPHORYLATION-0.600
  • DNA_REPAIR-0.500
  • G2M_CHECKPOINT-0.500
  • MTORC1_SIGNALING-0.500
  • MYC_TARGETS_V1-0.500
  • ALLOGRAFT_REJECTION-0.400
  • INTERFERON_GAMMA_RESPONSE-0.400
  • MYC_TARGETS_V2-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-HN-A2OB-01A-21R-A27Q-07
breast-umap@18
—A0.936
2X9cad7a78.ea9b.47b0.9d06.e5e696031cc3
lung-landscapes@6
—cohortA10.911
3SRR1313111
breast-umap@18
—A0.910
4BSR_15_0097_A4_S88
breast-umap@18
—A0.910
5TCGA-56-8626-01A-11R-2403-07
lung-landscapes@6
—cohortSQ10.908
6TCGA-EW-A1IX-01A-12R-A144-07
breast-umap@18
—A0.905
7TCGA-AC-A3W7-01A-11R-A22K-07
breast-umap@18
—A0.899
8s0095205
melanoma-umap@29
——0.898
9TCGA-BH-A28O-01A-11R-A22K-07
breast-umap@18
—A0.896
107900174d-af00-444f-a5b2-226a45f7e76a
colon-landscapes@1
——0.894

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 18 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
UV_RESPONSE_DN0.400Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.300Inavolisib— uncovered
HEDGEHOG_SIGNALING0.300Inavolisib— uncovered
KRAS_SIGNALING_DN0.300Remibrutinib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
NOTCH_SIGNALING0.300Inavolisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
APICAL_JUNCTION0.200Inavolisib— uncovered
COAGULATION0.200Binimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.200Idelalisib— uncovered
APICAL_SURFACE0.100Temsirolimus— uncovered
HYPOXIA0.100Idelalisib— uncovered
KRAS_SIGNALING_UP0.100Inavolisib— uncovered
P53_PATHWAY0.100Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.100Inavolisib— uncovered